Iranian Red Crescent Medical Journal

Published by: Kowsar

Effects of Coenzyme Q10 Supplementation on Serum Lipoproteins, Plasma Fibrinogen, and Blood Pressure in Patients With Hyperlipidemia and Myocardial Infarction

Mona Mohseni 1 , Mohamad Reza Vafa 1 , Seyed Javad Hajimiresmail 2 , Mitra Zarrati 3 , Abbas Rahimi Forushani 4 , Vida Bitarafan 3 and Farzad Shidfar 1 , *
Authors Information
1 Cardiology Division, Department of Internal Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, IR Iran
2 Cardiology Division, Department of Internal Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, IR Iran
3 Department of Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, IR Iran
4 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: October 01, 2014, 16 (10); e16433
  • Published Online: October 5, 2014
  • Article Type: Research Article
  • Received: November 27, 2013
  • Revised: March 14, 2014
  • Accepted: April 5, 2014
  • DOI: 10.5812/ircmj.16433

To Cite: Mohseni M, Vafa M R, Hajimiresmail S J, Zarrati M, Rahimi Forushani A, et al. Effects of Coenzyme Q10 Supplementation on Serum Lipoproteins, Plasma Fibrinogen, and Blood Pressure in Patients With Hyperlipidemia and Myocardial Infarction, Iran Red Crescent Med J. 2014 ; 16(10):e16433. doi: 10.5812/ircmj.16433.

Copyright © 2014, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Karthikeyan G, Teo KK, Islam S, McQueen MJ, Pais P, Wang X, et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study. J Am Coll Cardiol. 2009; 53(3): 244-53[DOI][PubMed]
  • 2. Shidfar F, Keshavarz A, Jallali M, Miri R, Eshraghian M. Comparison of the effects of simultaneous administration of vitamin C and omega-3 fatty acids on lipoproteins, apo A-I, apo B, and malondialdehyde in hyperlipidemic patients. Int J Vitam Nutr Res. 2003; 73(3): 163-70[PubMed]
  • 3. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31(23): 2844-53[DOI][PubMed]
  • 4. Figueras J, Monasterio J, Domingo E, Meneses B, Nieto E, Cortadellas J, et al. Prothrombotic profile in patients with vasospastic or non vasospastic angina and non significant coronary stenosis. Thromb J. 2011; 9: 10[DOI][PubMed]
  • 5. Shojaie M, Pourahmad M, Eshraghian A, Izadi HR, Naghshvar F. Fibrinogen as a risk factor for premature myocardial infarction in Iranian patients: a case control study. Vasc Health Risk Manag. 2009; 5: 673-6[PubMed]
  • 6. Levy HB, Kohlhaas HK. Considerations for supplementing with coenzyme Q10 during statin therapy. Ann Pharmacother. 2006; 40(2): 290-4[DOI][PubMed]
  • 7. Ankola DD, Viswanad B, Bhardwaj V, Ramarao P, Kumar MN. Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy? Eur J Pharm Biopharm. 2007; 67(2): 361-9[DOI][PubMed]
  • 8. Nahas R. Complementary and alternative medicine approaches to blood pressure reduction: An evidence-based review. Can Fam Physician. 2008; 54(11): 1529-33[PubMed]
  • 9. Mabuchi H, Nohara A, Kobayashi J, Kawashiri MA, Katsuda S, Inazu A, et al. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis. 2007; 195(2)-9[DOI][PubMed]
  • 10. Hagstromer M, Oja P, Sjostrom M. The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public Health Nutr. 2006; 9(6): 755-62[PubMed]
  • 11. Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia. 2002; 45(3): 420-6[DOI][PubMed]
  • 12. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007; 357(13): 1301-10[DOI][PubMed]
  • 13. Wang TD, Chen WJ, Chien KL, Seh-Yi Su SS, Hsu HC, Chen MF, et al. Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population. Am J Cardiol. 2001; 88(7): 737-43[PubMed]
  • 14. Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors. 2003; 18(1-4): 101-11[PubMed]
  • 15. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007; 49(23): 2231-7[DOI][PubMed]
  • 16. Kashyap M. Mechanistic studies of high-density lipoproteins. Ame J cardiol. 1998; 82(12): 42U-8U[DOI]
  • 17. Chapidze G, Kapanadze S, Dolidze N, Bachutashvili Z, Latsabidze N. Prevention of coronary atherosclerosis by the use of combination therapy with antioxidant coenzyme Q10 and statins. Georgian Med News. 2005; (118): 20-5[PubMed]
  • 18. Kato T, Yoneda S, Kako T, Koketsu M, Hayano I, Fujinami T. Reduction in blood viscosity by treatment with coenzyme Q10 in patients with ischemic heart disease. Int J Clin Pharmacol Ther Toxicol. 1990; 28(3): 123-6[PubMed]
  • 19. Playford DA, Watts GF, Croft KD, Burke V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis. 2003; 168(1): 169-79[PubMed]
  • 20. Heinrich J, Assmann G. Fibrinogen and cardiovascular risk. J Cardiovasc Risk. 1995; 2(3): 197-205[PubMed]
  • 21. Kaur S, Singh P, Indu V, Singla G. Fibrinogen, Lp(a), Microalbuminuria and Left Ventricular Mass Index: Cardiovascular Disease Risk factors in Diabetes. Indian J Clin Biochem. 2012; 27(1): 94-6[DOI][PubMed]
  • 22. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 1997; 17(10): 2020-8[PubMed]
  • 23. Singh RB, Niaz MA. Serum concentration of lipoprotein(a) decreases on treatment with hydrosoluble coenzyme Q10 in patients with coronary artery disease: discovery of a new role. Int J Cardiol. 1999; 68(1): 23-9[PubMed]
  • 24. Langsjoen P, Langsjoen P, Willis R, Folkers K. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med. 1994; 15 Suppl-72[PubMed]
  • 25. Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens. 1999; 13(3): 203-8[PubMed]
  • 26. Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J. 2001; 94(11): 1112-7[PubMed]
  • 27. Houston MC. Treatment of hypertension with nutraceuticals, vitamins, antioxidants and minerals. Expert Rev Cardiovasc Ther. 2007; 5(4): 681-91[DOI][PubMed]
  • 28. Hamilton SJ, Chew GT, Watts GF. Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diabetes Care. 2009; 32(5): 810-2[DOI][PubMed]
  • 29. Tiano L, Belardinelli R, Carnevali P, Principi F, Seddaiu G, Littarru GP. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur Heart J. 2007; 28(18): 2249-55[DOI][PubMed]
  • 30. Belardinelli R, Tiano L, Littarru GP. Oxidative stress, endothelial function and coenzyme Q10. Biofactors. 2008; 32(1-4): 129-33[PubMed]
  • 31. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res. 1989; 65(1): 1-21[PubMed]
  • 32. van Holten TC, Waanders LF, de Groot PG, Vissers J, Hoefer IE, Pasterkamp G, et al. Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. PLoS One. 2013; 8(4)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments